ACTIVE HALF-LIFE
2 days
CLASSIFICATION
Non-steroidal Aromatase Inhibitor
DOSAGE
0.5 - 2.5 mg/day
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Beligas - US
LAB TEST
See Document
WAREHOUSE
USA Warehouse 2
SUBSTANCE
Letrozole
Introducing Mono-Femara, a cutting-edge nonsteroidal agent renowned for its powerful estrogen synthesis inhibition and anticancer capabilities. As a third-generation aromatase inhibitor, it selectively and reversibly blocks aromatase, targeting the growth of estrogen-dependent breast cancer cells with precision.
Aromatase, a vital cytochrome P-450 enzyme located in the endoplasmic reticulum of various tissues?including premenopausal ovaries, the liver, and breast tissue?facilitates the conversion of androstenedione and testosterone into estrone and estradiol, marking the final step in estrogen production. Mono-Femara disrupts this process by competitively and reversibly binding to the heme component of aromatase, effectively inhibiting estrogen production while leaving mineralocorticoid and corticosteroid synthesis untouched.
Unlike tamoxifen, which acts as an anti-estrogen by blocking receptors, Mono-Femara directly inhibits estrogen production, making it a revolutionary choice for treating hormone receptor-positive or unknown receptor status local or metastatic breast cancer in postmenopausal women, as approved by the FDA. While side effects may mimic low estrogen symptoms, caution is warranted for long-term use due to potential osteoporosis risks; thus, doctors frequently prescribe medications like Fosamax alongside Mono-Femara to counteract these effects.
Remarkably, Mono-Femara can reduce estrogen levels by up to 98% while boosting testosterone levels, making it a favored choice among athletes and bodybuilders. It effectively combats water retention and the risk of gynecomastia that can arise during steroid cycles. However, it's essential to adhere to recommended doses, as exceeding 2.5 mg/day may temporarily lower libido, and prolonged use above 5 mg/day could lead to kidney complications.
Furthermore, Mono-Femara has shown promise in delaying the fusion of growth plates in adolescents, potentially enhancing the effectiveness of growth hormone, making it an innovative solution for treating short stature in children and teenagers.